Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Yee

Showing results (181-190 of 188) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 188 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker DiscoveryKathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E Lang, Andres Forero-Torres, Douglas Yee, et al.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialKatia Khoury, Jane L Meisel, Christina Yau, et al.
NPJ Breast Cancer|October 6, 2021
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Claudine Isaacs, Denise M Wolf, et al.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialRebecca A Shatsky, Meghna S Trivedi, Christina Yau, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
JAMA Oncology|July 24, 2020
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial, Douglas Yee, Angela M DeMichele, et al.
Pageof 19

Showing results (181-190 of 188) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 188 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker DiscoveryKathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
Nature Communications|November 6, 2021
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trialAmy S Clark, Christina Yau, Denise M Wolf, et al.
NPJ Breast Cancer|December 1, 2022
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancerJulie E Lang, Andres Forero-Torres, Douglas Yee, et al.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialKatia Khoury, Jane L Meisel, Christina Yau, et al.
NPJ Breast Cancer|October 6, 2021
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Claudine Isaacs, Denise M Wolf, et al.
Nature Medicine|September 14, 2024
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trialRebecca A Shatsky, Meghna S Trivedi, Christina Yau, et al.
JAMA Oncology|September 16, 2021
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical TrialW Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al.
JAMA Oncology|July 24, 2020
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial, Douglas Yee, Angela M DeMichele, et al.
Pageof 19